ALGS - Company ID 0001799448
The table below shows Aligos Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.19M | $3.61M | $6.19M | $0.00 | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $69.45M | $70.27M | $73.04M | $85.08M | $104.15M | $79.89M |
| SG&A |
Aligos Therapeutics, Inc. reported annual revenue of $2.19M for fiscal year 2025. That is down 39.5% from $3.61M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $20.72M |
| $22.83M |
| $30.62M |
| $26.41M |
| $28.53M |
| $17.94M |
| Operating income | -$87.98M | -$89.15M | -$88.13M | -$97.58M | -$128.32M | -$97.83M |
| Income tax | $314.00K | $331.00K | $795.00K | $106.00K | $143.00K | $161.00K |
| Net income | -$24.19M | -$131.21M | -$87.68M | -$96.05M | -$128.33M | -$108.54M |
| EPS (diluted) | -$2.45 | -$20.94 | -$34.20 | -$2.25 | - | - |